|
MMP11基因对肺腺癌诊断和预后的影响
|
Abstract:
目的:分析MMP11基因在肺腺癌中的表达特征,并评估其对肺腺癌诊断和预后的影响。方法:从TCGA数据库中下载肺腺癌转录组数据,利用生物信息学方法对MMP11在肺腺癌中的表达特征进行分析、并将该基因的表达特征与临床信息进行关联分析,进而对肺腺癌诊断及预后的影响进行系统分析。结果:MMP11基因在肺癌中高表达,对肺腺癌的诊断具有重要价值,但对肺腺癌预后的影响还有待于进一步研究。结论:MMP11基因有可能成为肺腺癌诊断相关的重要生物标记物。
Objective: To analyze the characteristics of MMP11 expression in lung adenocarcinoma and evaluate the impact on diagnosis and prognosis of lung adenocarcinoma. Method: The transcriptomic data of lung adenocarcinoma were downloaded from the TCGA database, and the expression characteristics of MMP11 in lung adenocarcinoma were analyzed by bioinformatic method, and then the expression characteristics of MMP11 were correlated with clinical information, so as to systematically analyze its influence on lung adenocarcinoma’ diagnosis and prognosis. Result: MMP11 gene is highly expressed in lung cancer and plays a significant role in the diagnosis of lung adenocarcinoma, but its effect on the prognosis of lung adenocarcinoma remains to be further elucidated. Conclusion: MMP11 gene may be an important biomarker in the diagnosis of lung adenocarcinoma.
[1] | Nagasaka, M. and Gadgeel, S.M. (2018) Role of Chemotherapy and Targeted Therapy in Early-Stage Non-Small Cell Lung Cancer. Expert Review of Anticancer Therapy, 18, 63-70. https://doi.org/10.1080/14737140.2018.1409624 |
[2] | Pirker, R. (2020) Chemotherapy Remains a Cornerstone in the Treatment of Nonsmall Cell Lung Cancer. Current Opinion in Oncology, 32, 63-67. https://doi.org/10.1097/CCO.0000000000000592 |
[3] | Imyanitov, E.N., Iyevleva, A.G. and Levchenko, E.V. (2021) Molecular Testing and Targeted Therapy for Non-Small Cell Lung Cancer: Current Status and Perspectives. Critical Reviews in Oncology/Hematology, 157, Article ID: 103194.
https://doi.org/10.1016/j.critrevonc.2020.103194 |
[4] | Reck, M. and Gatzemeier, U. (2004) Chemotherapy in Stage-IV NSCLC. Lung Cancer, 45, S217-S222.
https://doi.org/10.1016/j.lungcan.2004.07.972 |
[5] | Klastersky, J. and Awada, A. (2012) Milestones in the Use of Chemotherapy for the Management of Non-Small Cell Lung Cancer (NSCLC). Critical Reviews in Oncology/Hematology, 81, 49-57.
https://doi.org/10.1016/j.critrevonc.2011.02.002 |
[6] | Lemjabbar-Alaoui, H., Hassan, O.U., Yang, Y.-W. and Buchanan, P. (2015) Lung Cancer: Biology and Treatment Options. Biochimica et Biophysica Acta (BBA)-Reviews on Cancer, 1856, 189-210.
https://doi.org/10.1016/j.bbcan.2015.08.002 |
[7] | Moreira, A.L. and Eng, J. (2014) Personalized Therapy for Lung Cancer. CHEST, 146, 1649-1657.
https://doi.org/10.1378/chest.14-0713 |
[8] | Fang, B., Mehran, R.J., Heymach, J.V. and Swisher, S.G. (2015) Predictive Biomarkers in Precision Medicine and Drug Development against Lung Cancer. Chinese Journal of Cancer, 34, Article No. 26.
https://doi.org/10.1186/s40880-015-0028-4 |
[9] | Yang, H., Jiang, P., Liu, D., et al. (2019) Matrix Metalloproteinase 11 Is a Potential Therapeutic Target in Lung Adenocarcinoma. Molecular Therapy-Oncolytics, 14, 82-93. https://doi.org/10.1016/j.omto.2019.03.012 |
[10] | Liu, S.V., Subramaniam, D., Cyriac, G.C., Abdul-Khalek, F.J. and Giaccone, G. (2014) Emerging Protein Kinase Inhibitors for Non-Small Cell Lung Cancer. Expert Opinion on Emerging Drugs, 19, 51-65.
https://doi.org/10.1517/14728214.2014.873403 |
[11] | Dempke, W.C., Suto, T. and Reck, M. (2010) Targeted Therapies for Non-Small Cell Lung Cancer. Lung Cancer, 67, 257-274. https://doi.org/10.1016/j.lungcan.2009.10.012 |
[12] | Liu, X., Newton, R.C. and Scherle, P.A. (2011) Development of c-MET Pathway Inhibitors. Expert Opinion on Investigational Drugs, 20, 1225-1241. https://doi.org/10.1517/13543784.2011.600687 |
[13] | Rolfo, C., Ruiz, R., Giovannetti, E., et al. (2015) Entrectinib: A Potent New TRK, ROS1, and ALK Inhibitor. Expert Opinion on Investigational Drugs, 24, 1493-1500. https://doi.org/10.1517/13543784.2015.1096344 |
[14] | Mazieres, J., Barlesi, F., Filleron, T., et al. (2016) Lung Cancer Patients with HER2 Mutations Treated with Chemotherapy and HER2-Targeted Drugs: Results from the European EUHER2 Cohort. Annals of Oncology, 27, 281-286.
https://doi.org/10.1093/annonc/mdv573 |
[15] | Liu, D., Vokes, N.I. and Van Allen, E.M. (2017) Toward Molecularly Driven Precision Medicine in Lung Adenocarcinoma. Cancer Discovery, 7, 555-557. https://doi.org/10.1158/2159-8290.CD-17-0355 |
[16] | Tiseo, M., Loprevite, M. and Ardizzoni, A. (2004) Epidermal Growth Factor Receptor Inhibitors: A New Prospective in the Treatment of Lung Cancer. Current Medicinal Chemistry-Anti-Cancer Agents, 4, 139-148.
https://doi.org/10.2174/1568011043482106 |
[17] | Cabebe, E. and Wakelee, H. (2007) Role of Anti-Angiogenesis Agents in Treating NSCLC: Focus on Bevacizumab and VEGFR Tyrosine Kinase Inhibitors. Current Treatment Options in Oncology, 8, 15-27.
https://doi.org/10.1007/s11864-007-0022-4 |
[18] | Yagui-Beltrán, A., He, B., Raz, D., Kim, J. and Jablons, D.M. (2006) Novel Therapies Targeting Signaling Pathways in Lung Cancer. Thoracic Surgery Clinics, 16, 379-396. https://doi.org/10.1016/j.thorsurg.2006.07.001 |
[19] | Wu, D., Wang, D.C., Cheng, Y., et al. (2017) Roles of Tumor Heterogeneity in the Development of Drug Resistance: A Call for Precision Therapy. Seminars in Cancer Biology, 42, 13-19.
https://doi.org/10.1016/j.semcancer.2016.11.006 |
[20] | Sacco, J.J., Al-Akhrass, H. and Wilson, C.M. (2016) Challenges and Strategies in Precision Medicine for Non-Small-Cell Lung Cancer. Current Pharmaceutical Design, 22, 4374-4385. https://doi.org/10.2174/1381612822666160603014932 |
[21] | Lizardi, P.M., Forloni, M. and Wajapeyee, N. (2011) Genome-Wide Approaches for Cancer Gene Discovery. Trends in Biotechnology, 29, 558-568. https://doi.org/10.1016/j.tibtech.2011.06.003 |
[22] | Lee, E. and Moon, A. (2016) Identification of Biomarkers for Breast Cancer Using Databases. Journal of Cancer Prevention, 21, 235-242. https://doi.org/10.15430/JCP.2016.21.4.235 |
[23] | Bassiouni, W., Ali, M. A. and Schulz, R. (2021) Multifunctional Intracellular Matrix Metalloproteinases: Implications in Disease. The FEBS Journal, 288, 7162-7182. https://doi.org/10.1111/febs.15701 |
[24] | Murphy, G. and Nagase, H. (2008) Progress in Matrix Metalloproteinase Research. Molecular Aspects of Medicine, 29, 290-308. https://doi.org/10.1016/j.mam.2008.05.002 |
[25] | Quintero-Fabián, S., Arreola, R., Becerril-Villanueva, E., et al. (2019) Role of Matrix Metalloproteinases in Angiogenesis and Cancer. Frontiers in Oncology, 9, Article 1370. https://doi.org/10.3389/fonc.2019.01370 |
[26] | Zhang, X., Huang, S., Guo, J., et al. (2016) Insights into the Distinct Roles of MMP-11 in Tumor Biology and Future Therapeutics. International Journal of Oncology, 48, 1783-1793. https://doi.org/10.3892/ijo.2016.3400 |
[27] | Wang, Y., Wei, Y., Fan, X., et al. (2020) MicroRNA-125b as a Tumor Suppressor by Targeting MMP11 in Breast Cancer. Thoracic Cancer, 11, 1613-1620. https://doi.org/10.1111/1759-7714.13441 |